Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer
| العنوان: | Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer |
|---|---|
| المؤلفون: | Ryo Ariyasu, Takehiro Tozuka, Hiroaki Sakamoto, Takahiro Yoshizawa, Noriko Yanagitani, Makoto Nishio, Tsukasa Hasegawa, Shinya Uematsu, Hironori Ninomiya, Hiroshi Yoshida, Ken Uchibori, Satoru Kitazono, Atsushi Horiike, Yoshiaki Amino |
| المصدر: | In Vivo |
| بيانات النشر: | Anticancer Research USA Inc., 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, congenital, hereditary, and neonatal diseases and abnormalities, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Pembrolizumab, Protein Serine-Threonine Kinases, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, General Biochemistry, Genetics and Molecular Biology, Antineoplastic Agents, Immunological, AMP-Activated Protein Kinase Kinases, Carcinoma, Non-Small-Cell Lung, Internal medicine, PD-L1, Carcinoma, Humans, Medicine, skin and connective tissue diseases, Lung cancer, Retrospective Studies, Pharmacology, Lung, biology, business.industry, medicine.disease, medicine.anatomical_structure, biology.protein, Biomarker (medicine), Immunohistochemistry, Antibody, business, Research Article |
| الوصف: | Background/aim STK11/LKB1 mutation has been suggested as a poorly responding candidate biomarker of the anti-programmed cell death-1 (PD-1) antibody; however, the association between STK11/LKB1 expression and the effects of anti-PD-1 antibodies is uncertain. The aim of the study was to correlate the efficacy of pembrolizumab monotherapy and STK11/LKB1 expression in untreated patients with non-small-cell lung carcinoma (NSCLC) and high PD-ligand 1 expression. Patients and methods From February 2017 to January 2020, we retrospectively analyzed 30 previously untreated patients with NSCLC and a tumor proportion score (TPS) ≥50% treated with pembrolizumab monotherapy. STK11/LKB1 expression in tumor tissue was evaluated by immunohistochemistry. Results Twenty-three (76.7%) of the 30 patients were classified with low-STK11/LKB1 expression. The median progression-free survival and overall survival of patients with low-STK11/LKB1 expression was shorter than those with high-STK11/LKB1 expression, although the results were not statistically significant. The disease progression rate for the low-STK11/LKB1 group was higher than that of the high-STK11/LKB1 group. Conclusion STK11/LKB1 expression, as measured by immunohistochemistry, could be a useful biomarker associated with the efficacy of pembrolizumab monotherapy for patients with NSCLC and a TPS ≥50%. |
| تدمد: | 1791-7549 0258-851X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::622a6edfa48e415a1ea817554e2ec57fTest https://doi.org/10.21873/invivo.12131Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....622a6edfa48e415a1ea817554e2ec57f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17917549 0258851X |
|---|